세계의 유아성 경련 치료제 시장 규모, 점유율, 성장 분석, 치료제별, 유형별, 형태별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)

Global Infantile Spasms Therapeutics Market size was valued at USD 140.0 million in 2023 and is poised to grow from USD 149.24 million in 2024 to USD 248.85 million by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).

Market insights indicate a rising global demand for infantile spasms therapeutics, driven by an increasing prevalence of the condition in both developed and developing regions. Enhanced awareness among pediatricians and significant investments in R&D are propelling revenue growth, while advancements in drug formulations and the expansion of pediatric neurology services improve access to these therapies. Innovative tools such as advanced EEG, MRI, and genetic sequencing are facilitating earlier diagnoses. Support from government healthcare programs and nonprofit organizations is further amplifying awareness and funding for rare pediatric neurological disorders. However, challenges such as high treatment costs, a scarcity of trained specialists, potential side effects of existing treatments, and underdiagnosis in less developed areas may hinder market sales in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infantile Spasms Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Infantile Spasms Therapeutics Market Segments Analysis

Global Infantile Spasms Therapeutics Market is segmented by Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Anticonvulsants, Corticosteroids and Others. Based on Type, the market is segmented into Vigabatrin, Adrenocorticotropic Hormone and Phase III. Based on Dosage, the market is segmented into Solid and Liquid. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Clinic, Hospital and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Infantile Spasms Therapeutics Market

The increasing awareness among the medical community regarding infantile spasms has significantly improved the speed of diagnosis and treatment. Pediatricians and general practitioners are now more knowledgeable about the condition's symptoms and the critical need for prompt intervention, resulting in quicker referrals to specialists for suspected cases. This heightened clinical awareness has accelerated therapeutic responses, minimizing long-term neurodevelopmental impairment and promoting a greater reliance on therapeutics designed for infantile spasms. Consequently, this trend is driving growth in the global market for infantile spasms therapeutics, as more healthcare providers prioritize timely and effective care for affected infants.

Restraints in the Global Infantile Spasms Therapeutics Market

The Global Infantile Spasms Therapeutics market faces notable challenges due to the substantial side effects associated with treatments such as ACTH and vigabatrin. Adverse effects including adrenal suppression, vision loss, and immune suppression often create hesitation among healthcare providers and parents regarding the initiation of therapy. This apprehension can result in premature discontinuation or outright avoidance of treatment, especially in borderline cases. Additionally, the lack of safer long-term alternative therapies exacerbates these concerns, impacting overall treatment compliance and limiting the market's growth potential. Hence, these factors represent a significant restraint within the sector.

Market Trends of the Global Infantile Spasms Therapeutics Market

The Global Infantile Spasms Therapeutics market is witnessing a significant shift towards precision medicine and genetic profiling, driven by advances in molecular diagnostics. This trend underscores the importance of personalized treatment strategies, with genetic testing and next-generation sequencing playing crucial roles in identifying the underlying causes of infantile spasms. As these technologies become more affordable and accessible, pharmaceutical companies are increasingly investing in mutation-targeted therapies, enhancing the effectiveness of treatments. This strategic focus on tailored approaches is expected to shape the future of the market, leading to improved patient outcomes and fostering innovation in therapeutic options for infantile spasms.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Infantile Spasms Therapeutics Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Anticonvulsants
• Corticosteroids
• Others

Global Infantile Spasms Therapeutics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Vigabatrin
• Adrenocorticotropic Hormone
• Phase III

Global Infantile Spasms Therapeutics Market Size by Dosage & CAGR (2025-2032)

• Market Overview
• Solid
• Liquid

Global Infantile Spasms Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Infantile Spasms Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Clinic
• Hospital
• Others

Global Infantile Spasms Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Infantile Spasms Therapeutics Market Size & CAGR (2025-2032)

• North America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Amneal Pharmaceuticals LLC (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals, Inc. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSN Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ovid Therapeutics (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGPharma Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merz Therapeutics (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations